| 3.55 0.04 (1.14%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.44 | 1-year : | 4.77 |
| Resists | First : | 3.8 | Second : | 4.09 |
| Pivot price | 3.74  |
|||
| Supports | First : | 3.34 | Second : | 2.78 |
| MAs | MA(5) : | 3.58 |
MA(20) : | 3.75  |
| MA(100) : | 4.72 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 16.1 |
D(3) : | 18.6 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 14.15 | Low : | 3.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RCEL ] has closed above bottom band by 13.2%. Bollinger Bands are 65.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.63 - 3.66 | 3.66 - 3.68 |
| Low: | 3.45 - 3.48 | 3.48 - 3.5 |
| Close: | 3.52 - 3.56 | 3.56 - 3.59 |
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Thu, 04 Dec 2025
RCEL: Reimbursement resolution and cost discipline set the stage for accelerated growth in 2026 - TradingView
Wed, 03 Dec 2025
Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, - GlobeNewswire
Mon, 17 Nov 2025
Avita Medical Inc. (NASDAQ:RCEL) Given Average Rating of "Reduce" by Brokerages - MarketBeat
Sun, 09 Nov 2025
AVITA Medical, Inc. (NASDAQ:RCEL) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st
Wed, 05 Nov 2025
What To Expect From AVITA Medical Inc (RCEL) Q3 2025 Earnings - Yahoo Finance
Mon, 13 Oct 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 3.02e+007 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 3,160 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.003e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -67.1 % |
| Operating Margin | -53.7 % |
| Return on Assets (ttm) | -36.4 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 7.24e+007 % |
| Gross Profit (p.s.) | -7.7 |
| Sales Per Share | 452.28 |
| EBITDA (p.s.) | 3.67455e+007 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -26.63 |
| Dividend | 0 |
| Forward Dividend | 3.02e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|